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OBJECTIVES: Direct and indirect costs caused by candidemia in ICU patients are
currently unknown. We performed an analysis comparing costs depending on the
type of antifungal treatment. METHODS: Data of patients from the University Hos-
pital of Cologne with at least one blood culture positive for Candidaspp. while stay-
ing on the ICU between 2005 and 2010 were documented into a database. Indirect
costs caused by illness-conditioned disability and death before retirement age
were calculated using the friction cost method. Analysis was split for patients
treated with new antifungals (i.e. echinocandins, liposomal amphotericin B, or
voriconazole) or conventional antifungals (i.e. amphotericin B deoxycholate or
fluconazole). RESULTS: Out of 147 identified patients, 45 received new and 66 con-
ventional antifungals, and 36 patients were excluded from analysis (21 died within
96 hours after positive blood culture, seven were rated as contamination, eight
patient files were missing). Mean APACHE IV score was 113 (105.7-121.2) vs. 96
(90.3-100.8, P0,001). Mean direct costs per patient in the new and the conven-
tional antifungal groups were as follows: ICU treatment 24,922 € (95% CI: 17,054-
31,789 €) vs. 17,971 € (95% CI: 13,203-22,740 €,Pn.s.), antifungal treatment 4,271 €
(95% CI: 2,983-5,560 €) vs. 2,079 € (95% CI: 1,246-2,912€, P0.005), total direct costs
41,060 € (95% CI: 30,184-51,935 €) vs. 28,885 € (95% CI: 22,116-35,654 €, n.s.), indirect
costs per patient due to productivity loss of illness-related disability 1,202 € (95% CI:
474-1,930 €) vs. 1,087 € (95% CI: 570-1,604 €, n.s.), due to death before retirement age
1,047 € (95% CI: 236-1,858 €) vs. 1,309 € (95% CI: 584-2,034 €, n.s.). Twenty-five (56%)
and 33 (50%) patients survived hospitalization, 20 (44%) and 22 (33%) patients sur-
vived one year after diagnosis. CONCLUSIONS: Our cost-of-illness analysis shows
the high treatment costs of patients with candidemia. In our analysis, treatment
with new antifungals was associated with higher costs. Although sicker patients
were significantly more likely to receive new antifungals, outcomes were compa-
rable to less sick patients treated with conventional antifungals.
PIN29
LENGTH OF STAY AND COST DUE TO RECURRENT CLOSTRIDIUM DIFFICILE
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OBJECTIVES: The European Society of Clinical Microbiology and Infectious Dis-
eases (ESCMID) has highlighted recurrence as the most important problem in the
management of CDI. There is lack of knowledge regarding length of stay (LOS) and
cost associated with recurrent clostridium difficileinfection (CDI). Our objective was
to collect real life data for estimating days of hospitalization and costs attributable
to recurrent CDI. METHODS: A prospective observational study was conducted at
Helsinki University Central hospital during February 2007 and May 2008. The CDI
patients were identified from the microbiology laboratory reports to one of the six
acute wards included in the study. Only health care associated CDI cases were
included. The recurrence of CDI was defined as a new positive sample less than
eight weeks after the first one. The patients had no previous history of CDI one
month prior to first positive sample. Resource use data were extracted from the
medical records using Appropriateness Evaluation Protocol-based methodology.
Unit costs were obtained from literature, hospital administration, laboratory and
pharmacy. RESULTS: During the 16 months study period, 72 CDI patients were
identified, which corresponds to incidence of 0.7-3.8/1,000 patient days. Of those, 7
% were recurrent cases (5 patients). Mean LOS for recurrent cases was 3.17 times
longer than among non-recurrent cases. The mean incremental cost for recurrent
CDI was €6,800 which was 2.52 times higher than the average incremental cost of
the total CDI population (€2,700, and €2,300 for not recurrent cases). Most of the
resource use came from additional treatment days (94% of total cost). Other costs
were due to laboratory tests, medication and isolation. CONCLUSIONS: Recurrent
CDI is associated with significantly longer LOS and higher costs compared to the
average CDI population. The main cost driver between the groups was length of
stay.
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OBJECTIVES: Varicella (chickenpox) is one of the most common illness of children,
most typical for the 2-6 years age group. In 2.5% of healthy children complications
occur (bacterial overinfection, meningitis, meningoencephalitis, pneumonia are
the most frequent complications), the infection is potentially life-threatening
among healthy and might be directly life-threatening among immuncompromit-
ted patients. Varicella can be prevented by live attenuated vaccine. According to
WHO recommendation these vaccines are safe, effective and should be imple-
mented into the recommended age-related vaccines. International guidelines rec-
ommend the vaccine, although it is not part of the obligatory vaccination schedule
in Hungary, nor is covered by reimbursement.METHODS: In our research we aimed
to examine the consequences of varicella. We calculated the disease of burden in
Hungary by the utilization of evidences from literature, health care provision data
of Hungarian National Health Insurance Fund Administration as well as question-
naire survey. RESULTS: Direct and indirect costs of varicella-related health care
provision are significant according to our analysis based on HNHIFA data and ques-
tionnaire survey. Our results showed that annually almost 1 billion HUF expendi-
ture caused by varicella. CONCLUSIONS: Our analysis determines the disease bur-
den of varicella and emphasizes the importance of prevention. Increasing the rate
of vaccination, epidemics can be held up, majority of the serious and complicated
cases can be avoided, thus their provisional cost consequence can be decreased.
From the societal viewpoint the costs that can be saved by vaccination are even
higher as remarkable reduction can be achieved in indirect costs due to the rare,
less serious and shorter duration breakthrough cases.
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OBJECTIVES: About 50 million dengue infections occur every year worldwide. New
dengue vaccines are currently in development and policymakers need appropriate
economic studies to determine their potential impact. This study aims to assess
the burden of dengue disease in Colombia and its costs. METHODS: We estimated
the disease burden of dengue (D) and severe dengue (SD) in Colombia for 2011-2014
based on a dynamic model designed with the best available evidence and validated
with the occurrence data. The annual number of D and SD cases receiving medical
care were determined. We calculated the average cost of care per patient with D
and SD based on a bottom-up costing of cases attended in the Colombian health
facilities, additional costs were estimated from programs of vector control dengue
at different administrative levels. Based on the occurrence of disease and extrap-
olation of national vector control programs we estimated a total annual cost of
burden of dengue in Colombia. RESULTS: Our dengue model estimated in 2011
34,751 D consults (13,900 outpatients, 20,851 inpatients), 988 SD cases, and 102
(78-123) deaths due to dengue. In 2012 22,247 D (8899 in- 13,348 out-patients), 863
SD, and 103 (79-124) deaths. In 2013 27,588 D (11,035 in- 16,553 out-patients), 1032
SD and 105 (80-126) deaths. Finally in 2014 25,957 D (10,383 in- 15,574 out-patients),
913 SD, and 106 (80-127) deaths. The total attention costs in 2011 raised to US$ 16.86
million. That year the total cost of Dengue’s vector program amounted to US$
37.08-42.41 million. The total annual cost of dengue would amount to US$ 53.94-
59.27 million in a year without outbreak. CONCLUSIONS: Burden of dengue disease
in Colombia involves a high economic impact to the health system. In 2011 be-
tween 28.4-31.3% correspond to medical attention cost and between 68.7-71.6% are
due to dengue vector control program.
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OBJECTIVES: Recent randomized, placebo-controlled clinical trials (SPRINT-2; RE-
SPOND-2) demonstrated that the triple combination of peginterferon (PEG), ribavi-
rin (RBV) and boceprevir (BOC) was more efficacious than standard therapy of
PEG-RBV alone in treatment of patients with genotype 1 chronic hepatitis C virus
(GI HCV) infection. The objective of this study was to evaluate the cost-effective-
ness of triple therapy in both treatment-naive and treatment-experienced patients
in Hungary. METHODS: A Markov-model was developed to investigate the long-
term clinical benefits and the cost-effectiveness of the triple therapy from the
Hunagarian payer perspective. Health states within the model were defined using
METAVIR fibrosis scores (F0–F4), decompensated cirrhosis (DC), hepatocellular car-
cinoma (HCC), liver trasnsplant (LT), and liver-realted deaths (LD). Efficacy data was
estimated using SPRINT-2 and RESPOND-2 studies, and disease progression rates
and utilities used in the model were estimated from published studies. Data on
probability of liver-transplantation and cost estimates were based on an analysis of
the Hungarian Sick Fund database.. Costs and benefits were discounted at 5%.
RESULTS: Triple therapy is projected to increase the life expectancy by 0.98 and
2.39 years and the quality-adjusted life years (QALY) by 0.59 and 1.13 in comparison
with treatment with PEG-RBV in treatment-naive and treatment-experienced pa-
tients, respectively. The corresponding incremental cost-effectiveness ratios were
HUF7,747,962 (EUR 26,717) and HUF5,888,240 (EUR20,304) per QALY, respectively.
The lifetime incidence of severe liver disease events (DC, HCC, LT, LD) decreased by
41% and 61% in these patient groups in comparison with treatment with PEG-RBV
alone.CONCLUSIONS: The addition of boceprevir to standard therapy for the treat-
ment of patients with G1 chronic HCV infection in Hungary is cost-effective using
a commonly used willingness to pay threshold of HUF8,48 million (3x GDP per
capita).
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OBJECTIVES:Data on actual cost of illness studies for HIV-infection in Germany are
lacking. The objective of CORSAR is to collect comprehensively and prospectively
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